Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PLEASANTON, Calif. AP) — 10x Genomics Inc. TXG) on Wednesday reported a loss of $49 million in its fourth quarter.

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and to advance human health. Cited in more than 7,000 research papers, ...

These factors together underpin the positive long-term outlook for 10x Genomics. Souda covers the Healthcare sector, focusing on stocks such as Revvity, Exact Sciences, and Natera. According to ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Super Micro Computer declined 1.7% to $46.47 ... The company also launched its latest data center AI chip. 10x Genomics fell 25% after the life-sciences technology company said it expects third ...

20:39 EST Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics (TXG) today Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...